In his recent work, we have developed machine-learning based scoring models to predict allogeneic donor response to G-CSF for stem cell mobilization at the early donor screening stage. He is interested in further expanding these models in the autologous settings in patients with multiple myeloma or lymphoma, among which the poor mobilization rate is even higher (up to 20%). Another translational research interest is in cellular therapy. Chimeric Antigen Receptor (CAR) T-Cell Therapy has become a new class of therapeutic agent for patients with hematologic malignancies. However, some patients develop severe cytokine release syndrome (CRS), one of the most common CAR T-cell therapy-associated toxicity. Dr. Xiang is interested to study the biology of CRS and to identify new therapeutic targets to block CRS through CRISPR screening and single-cell RNA sequencing technology.